You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Novel QcrB Inhibitors for the Treatment of Tuberculosis

    SBC: LGENIA INC.            Topic: NIAID

    Abstract Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the biggest killer among infectious diseases. TB is also responsible for a quarter of all deaths associated with Antimicrobial Resistance (AMR). It is projected that by 2050, 75 million people, or one person every 12 seconds, will die due to AMR associated with TB. Long treatment times and increasing resistance to TB drugs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents

    SBC: Grannus Therapeutics Inc            Topic: NCI

    Abstract The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small molecule inhibitors of Hsp90 have entered clinical trials for ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Developing high throughput measurement of thiopurine in DNA by mass spectrometry

    SBC: Tymora Analytical Operations, LLC            Topic: 400

    PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)

    SBC: Tymora Analytical Operations, LLC            Topic: NIA

    PROJECT SUMMARY The rising number of Americans currently living with Alzheimer’s disease (AD) demands pressing therapeutic and diagnostic solutions. The consensus is that early detection is critical to delay and better manage the disease. The recent discovery of extracellular vesicles (EVs) and their potentially important cellular functions in neuronal-glial communication, synaptic plasticity, o ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community

    SBC: EPERTURE LLC            Topic: NIA

    Project Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Antioxidant enzyme-loaded Pro-NP for treatment of TBI.

    SBC: ProTransit Nanotherapy, LLC            Topic: 106

    ABSTRACT Traumatic brain injury (TBI) is one of the leading causes of death and disability worldwide and comes with a significant economic burden associated with emergency room visits and hospitalizations. Oxidative stress- mediated secondary injury post-TBI is a considerable risk factor for mortality and long-term impairment. Immediately following TBI, a cascade of biological responses leads to i ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization

    SBC: Breezmed            Topic: 104

    ABSTRACT This STTR Phase I project uses mixed-method formative evaluation strategies to develop, test, and evaluate an alpha prototype of Breezmed, a point-of-care electronic prior authorization web-based platform. Prior authorization burdens the current medical system, hampering a provider’s ability to efficiently prescribe medication and in a timely fashion. This often leads to treatment non-c ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Prevention of White Matter Injury in Premature Infants

    SBC: Medosome Biotec, LLC            Topic: NICHD

    ABSTRACTUp toof low birth weight preterm infants manifest some form of periventricular white matter injuryPWMImaking it the most common form of brain injury affecting premature infantsPWMI is associated with significant morbidityas affected individuals may have profound intellectual impairment and cerebral palsyHighlighting the magnitude of PWMIeach year more thaninfants are born prematurely in th ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Personalized Bioreactor for Cell Culturing in Alginate Tubes

    SBC: CellGro Technologies, LLC            Topic: 400

    PROJECT SUMMARY ABSTRACT SignificanceCell therapy is expected to become an important method to treat chronic diseases such as diabetesrheumatoid arthritisretinal diseases like macular degeneration and certain types of cancersThe cell therapy market in general is projected to become a $billion industry byHuman pluripotent stem cellshPSCsare of particular importance since their utility as a source f ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Stem Cell-derived Cell-free Therapeutic for Stress Urinary Incontinence

    SBC: NeuroFx, Inc.            Topic: 400

    Abstract Stress urinary incontinenceSUIcan result from a combinatorial neuromuscular injury to the pudendal nerve and the muscle it innervatesthe external urethral sphincterEUScompounded by the biochemical effects of agingThe mechanisms of SUI development include incomplete pudendal nerve regeneration and EUS sphincter repair from the maternal polytrauma of childbirth as well as biochemical change ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government